Reddy Saravanan Sampoornam Pape, Francis Delfin Lovelina, Thirumoorthi Harshini, Rathi Manish, Singh Harjeet, Karmakar Shaswata, Pradhan Shaili
Department of Periodontology, Army Dental Centre (Research & Referral), New Delhi, India.
Saveetha Dental College & Hospitals, Saveetha University, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, Tamil Nadu, India.
Clin Exp Dent Res. 2025 Jun;11(3):e70134. doi: 10.1002/cre2.70134.
The aim of this study was to evaluate the effectiveness of recombinant human bone morphogenetic protein-2 (rhBMP-2) coated biphasic calcium phosphate (BCP) in socket preservation in comparison to BCP.
Patients who underwent extraction of maxillary premolars were randomized to receive rhBMP-2/BCP (n = 15) and BCP alone (n = 15). All sites were primarily closed using a pedicled connective tissue flap. Biopsy was carried out in patients at 3 (n = 10), 6 (n = 10), and 9 (n = 10) months.
At 3 months, BMP and non-BMP groups had 3.17% and 3.12% new bone formation, respectively, and 3.8% and 37.85% of residual grafts, respectively, and 25.86% and 25.99% connective tissue component, respectively. At 6 months, both groups revealed 67.42% and 16.55% essential bone growth, 1.74% and 3.04% of residual graft, and 1.3% and 67% connective tissue component, respectively. At 9 months, the BMP group revealed 93.6% new bone formation, 0.68% residual graft, and 1.9% connective tissue component, while the non-BMP groups had 23.35% new bone formation, 4.45% residual graft, and 44.06% connective tissue component.
This study demonstrated that rhBMP-2 coated BCP significantly enhanced early graft substitution in socket preservation sites compared to BCP alone. There was a significantly higher percentage of new bone formation in the rhBMP-2/BCP group both at 6 and 9 months. Additionally, the rhBMP-2/BCP group exhibited faster resorption of the graft material and earlier maturation of newly formed bone. These findings strongly suggest that rhBMP-2/BCP can be an effective treatment modality for socket preservation, promoting predictable and accelerated bone regeneration.
本研究旨在评估重组人骨形态发生蛋白-2（rhBMP-2）涂层双相磷酸钙（BCP）与BCP相比在牙槽窝保存中的有效性。
将接受上颌前磨牙拔除术的患者随机分为两组，分别接受rhBMP-2/BCP（n = 15）和单纯BCP（n = 15）治疗。所有术区均首先使用带蒂结缔组织瓣进行封闭。在术后3个月（n = 10）、6个月（n = 10）和9个月（n = 10）对患者进行活检。
在3个月时，BMP组和非BMP组的新骨形成率分别为3.17%和3.12%，剩余移植物比例分别为3.8%和37.85%，结缔组织成分比例分别为25.86%和25.99%。在6个月时，两组的主要骨生长率分别为67.42%和16.55%，剩余移植物比例分别为1.74%和3.04%，结缔组织成分比例分别为1.3%和67%。在9个月时，BMP组的新骨形成率为93.6%，剩余移植物比例为0.68%，结缔组织成分比例为1.9%；而非BMP组的新骨形成率为23.35%，剩余移植物比例为4.45%，结缔组织成分比例为44.06%。
本研究表明，与单纯BCP相比，rhBMP-2涂层BCP在牙槽窝保存部位显著增强了早期移植物替代。在6个月和9个月时，rhBMP-2/BCP组的新骨形成百分比均显著更高。此外，rhBMP-2/BCP组的移植物材料吸收更快，新形成骨的成熟更早。这些发现强烈表明，rhBMP-2/BCP可作为牙槽窝保存的一种有效治疗方式，促进可预测且加速的骨再生。
